MDxHealth Announces Pricing of Offering of ADSs in the United States
NEWS RELEASE – REGULATED INFORMATION INSIDE INFORMATION FEBRUARY 3, 2023, 8:00 am ET/ 14:00 CET IRVINE, CA, and HERSTAL, BELGIUM – February 3, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH) (“mdxhealth” or the “Company“), a commercial-stage precision diagnostics company, today announced that it has priced a registered public offering of 10,000,000 American Depositary Shares (“ADSs”) (each representing […]
MDxHealth Announces Launch of Offering of ADSs in the United States
NEWS RELEASE – REGULATED INFORMATION INSIDE INFORMATION FEBRUARY 1, 2023, 4PM ET/ 22:00 CET IRVINE, CA, and HERSTAL, BELGIUM –February 1, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH) (“mdxhealth” or the “Company“), a commercial-stage precision diagnostics company, announced the launch of a proposed offering of $40,000,000 of American Depositary Shares (“ADSs“) (each representing 10 ordinary shares of […]
MDxHealth Provides Updated and Supplemental Financial Information Related to Acquisition of GPS Test
NEWS RELEASE –REGULATED INFORMATION 20 JANUARY 2023, 1:00 am ET / 7:00 am CET IRVINE, CA, and HERSTAL, BELGIUM – January 20, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today provided supplemental information related to its acquisition of the Oncotype DX® GPS (Genomic Prostate Score®) test on August 2, 2022 (the “GPS […]
MDxHealth Reports Preliminary 2022 Revenues and Reaffirms 2023 Revenue Guidance
NEWS RELEASE – INSIDE AND REGULATED INFORMATION 9 JANUARY 2023, 4PM ET / 22:00 CET IRVINE, CA, and HERSTAL, BELGIUM – January 9, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today reported preliminary 2022 revenues and reaffirmed its 2023 revenue guidance. The Company expects to report 2022 revenues of approximately $37 […]
Mdxhealth files U.S. Shelf Registration on Form F-3
NEWS RELEASE – REGULATED INFORMATION December 19, 2022, 4:00PM EDT / 22:00 CET IRVINE, CA, and HERSTAL, BELGIUM – December 19, 2022 – Mdxhealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today announced that it has filed a U.S. “shelf” registration statement for its American Depositary Shares (“ADSs”), each representing 10 ordinary shares. The […]
MDxHealth Provides Business Update
NEWS RELEASE – INSIDE AND REGULATED INFORMATION29 NOVEMBER 2022, 4:00PM EDT / 22:00 CET MDxHealth Provides Business Update IRVINE, CA, and HERSTAL, BELGIUM – November 29, 2022 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today provided clinical and reimbursement product developments, updated guidance for 2022, and initial guidance for 2023. Select mdx […]
MDxHealth Reports Q3-2022 Results
NEWS RELEASE – REGULATED INFORMATION 27 OCTOBER 2022, 4:00PM EDT / 22:00 CET MDxHealth Reports Q3-2022 Results IRVINE, CA, and HERSTAL, BELGIUM – October 27, 2022 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today announced its financial results for the third quarter ended September 30, 2022. Michael K. McGarrity, CEO of mdxhealth, […]
MDxHealth Reports Half Year 2022 Results
NEWS RELEASE – REGULATED INFORMATION 25 AUGUST 2022, 4:00PM EDT, 22:00 CET MDxHealth Reports Half Year 2022 Results IRVINE, CA, and HERSTAL, BELGIUM – August 25, 2022 – MDxHealth SA (NASDAQ/Euronext: MDXH) (“mdxhealth” or the “Company“), a commercial-stage precision diagnostics company, today announced its financial results for the half year ended June 30, 2022. Michael […]
Mdxhealth’s New Share Capital Amount and New Number of Shares
NEWS RELEASE – REGULATED INFORMATION August 19, 2022, 4:00 PM EDT / 22:00 CET Mdxhealth‘s New Share Capital Amount and New Number of Shares IRVINE, CA, and HERSTAL, BELGIUM – August 19, 2022 – MDxHealth SA (NASDAQ/Euronext: MDXH) (“mdxhealth” or the “Company“), a commercial-stage precision diagnostics company, today a announces, in accordance with Article 15 […]
Mdxhealth Acquires Oncotype DX® GPS Prostate Cancer Business from Exact Sciences and Reports Preliminary Half Year 2022 Results
NEWS RELEASE – INSIDE AND REGULATED INFORMATION August 2, 2022, 4:00PM EDT / 22:00 CET Mdxhealth Acquires Oncotype DX® GPS Prostate Cancer Business from Exact Sciences and Reports Preliminary Half Year 2022 Results Solidifies leadership in the precision diagnostics urology market Provides the most comprehensive menu of advanced molecular tests for urology in prostate cancer Enhances scale […]
